Acceleron Pharma (XLRN) Misses Q4 EPS by 32c

Acceleron Pharma (NASDAQ: XLRN) reported Q4 EPS of ($0.55), $0.32 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $9.6 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• Dyadic International, Inc. (DYAI) Misses Q2 EPS by 2c
• NeOnc Phase 2a brain cancer trial shows 48.9% survival vs. 20% benchmark